What the FDA labels say about taking them together
Glyburide and rifampin
Glyburide's FDA label of July 1, 2021 names rifampin in its drug interactions section; the rifampin label PlainMeds reads does not name glyburide.
Check it at the source: the glyburide FDA label on DailyMed (effective July 1, 2021, TEVA Pharmaceuticals USA Inc); the rifampin FDA label on DailyMed (effective February 11, 2026, Lupin Pharmaceuticals, Inc.).
What does the glyburide label say about rifampin?
Glyburide label, drug interactionsRifampin may worsen glucose control of glyburide because rifampin can significantly induce metabolic isozymes of glyburide such as CYP2C9 and 3A4.
Source: FDA drug label (Glyburide), NDA017532 (Sanofi Aventis Us), as published by TEVA Pharmaceuticals USA Inc, effective July 1, 2021 (SPL set 50d16f1d-c814-4411-8749-62561321ecce), via openFDA; the full label on DailyMed
What does the rifampin label say about glyburide?
Rifampin's label (effective February 11, 2026) does not name glyburide in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (rifampin), Lupin Pharmaceuticals, Inc., effective February 11, 2026 (SPL set b56004f0-f23d-47f6-80c7-39884fccbccc), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Glyburide | Rifampin | |
|---|---|---|
| Labeled for | Type 2 diabetes | n/a |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $0.0643 per tablet 5 mg tablet | $0.679 per capsule 300 mg capsule |
| Shortage now | A presentation being discontinued | In shortage |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once